Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SK Hynix Shares Fall as Workers Reject Wage Deal 
(4) - EconoTimes)
Add as a preferred source on Google
CAMBRIDGE, Mass., April 30, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on April 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to forty individuals hired by Sarepta in April 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 170,959 shares of Sarepta's common stock. The options have an exercise price of $76.36 per share, which is equal to the closing price of Sarepta's common stock on April 30, 2018. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
